Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

Cyclophosphamide 24Mycophenolic Acid 15fludarabine phosphate 14fludarabine 13Whole-Body Irradiation 13Tacrolimus 12Rituximab 12Melphalan 12Filgrastim 11Cyclosporine 11Busulfan 11Radiotherapy 10Peripheral Blood Stem Cell Transplantation 10Antilymphocyte Serum 10Methotrexate 9Doxorubicin 9Gemcitabine 8Etoposide 8Brentuximab Vedotin 8Sirolimus 7pembrolizumab 6Vinblastine 6Nivolumab 6Methylprednisolone 6Granulocyte Colony-Stimulating Factor 6Alemtuzumab 6Dacarbazine 5Cytarabine 5Cord Blood Stem Cell Transplantation 5Carmustine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hodgkin Disease × givinostat × Clear all
NCT00496431 2022-01-27

phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

Italfarmaco

Phase 1/2 Terminated
19 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡